Gene Products, tat

• 

  Subject Areas on Research

  • A comparison of regulatory features in primate lentiviruses. 
  • A functional genetic approach suggests a novel interaction between the human immunodeficiency virus type 1 (HIV-1) Tat protein and HIV-1 TAR RNA in vivo. 
  • A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. 
  • A small circular TAR RNA decoy specifically inhibits Tat-activated HIV-1 transcription. 
  • Activation of tat-defective human immunodeficiency virus by ultraviolet light. 
  • Amino acid sequence requirements of peptides that inhibit polyglutamine-protein aggregation and cell death. 
  • An in vitro transcription system that recapitulates equine infectious anemia virus tat-mediated inhibition of human immunodeficiency virus type 1 Tat activity demonstrates a role for positive transcription elongation factor b and associated proteins in the mechanism of Tat activation. 
  • Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes. 
  • Antisense inhibition of P-glycoprotein expression using peptide-oligonucleotide conjugates. 
  • CA150, a nuclear protein associated with the RNA polymerase II holoenzyme, is involved in Tat-activated human immunodeficiency virus type 1 transcription. 
  • Canine cyclin T1 rescues equine infectious anemia virus tat trans-activation in human cells. 
  • Chronic Systemic Immune Dysfunction in African-Americans with Small Vessel-Type Ischemic Stroke. 
  • Concerted motions in HIV-1 TAR RNA may allow access to bound state conformations: RNA dynamics from NMR residual dipolar couplings. 
  • Conjugates of antisense oligonucleotides with the Tat and antennapedia cell-penetrating peptides: effects on cellular uptake, binding to target sequences, and biologic actions. 
  • Does HIV-1 Tat induce a change in viral initiation rights? 
  • Does the human immunodeficiency virus Tat trans-activator contain a discrete activation domain? 
  • Durhamycin A, a potent inhibitor of HIV Tat transactivation. 
  • Evidence that Par-4 participates in the pathogenesis of HIV encephalitis. 
  • Fluorescent peptide displacement as a general assay for screening small molecule libraries against RNA. 
  • Functional analysis of interactions between Tat and the trans-activation response element of human immunodeficiency virus type 1 in cells. 
  • Functional analysis of the Tat trans activator of human immunodeficiency virus type 2. 
  • Functional characterization of a complex protein-DNA-binding domain located within the human immunodeficiency virus type 1 long terminal repeat leader region. 
  • Functional differences between human and bovine immunodeficiency virus Tat transcription factors. 
  • Functional similarities between HIV-1 Tat and DNA sequence-specific transcriptional activators. 
  • Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing. 
  • Generation of nuclease resistant circular RNA decoys for HIV-Tat and HIV-Rev by autocatalytic splicing. 
  • Genetic analysis of the cofactor requirement for human immunodeficiency virus type 1 Tat function. 
  • Genetic evidence that the Tat proteins of human immunodeficiency virus types 1 and 2 can multimerize in the eukaryotic cell nucleus. 
  • HIV-1 auxiliary proteins: making connections in a dying cell. 
  • Highly divergent lentiviral Tat proteins activate viral gene expression by a common mechanism. 
  • Human immunodeficiency virus type 1 Tat activity in human neuronal cells: uptake and trans-activation. 
  • Human immunodeficiency virus type 1 Tat-dependent activation of an arrested RNA polymerase II elongation complex. 
  • Identification of a novel cell attachment domain in the HIV-1 Tat protein and its 90-kDa cell surface binding protein. 
  • Identification of a novel human zinc finger protein that specifically interacts with the activation domain of lentiviral Tat proteins. 
  • Impact of antibody quality and anamnestic response on viremia control post-challenge in a combined Tat/Env vaccine regimen in rhesus macaques. 
  • Intrinsic activity of human immunodeficiency virus type 1 protease heterologous fusion proteins in mammalian cells. 
  • Kinetics of human immunodeficiency virus type 1 (HIV-1) DNA and RNA synthesis during primary HIV-1 infection. 
  • Loss of G(1)/S checkpoint in human immunodeficiency virus type 1-infected cells is associated with a lack of cyclin-dependent kinase inhibitor p21/Waf1. 
  • Mutational analysis of the conserved basic domain of human immunodeficiency virus tat protein. 
  • Mutational definition of the human immunodeficiency virus type 1 Rev activation domain. 
  • NF-kappaB p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. 
  • Phosphorylation of the rev gene product of human immunodeficiency virus type 1. 
  • Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. 
  • Potent and specific inhibition of human immunodeficiency virus type 1 replication by RNA interference. 
  • Potent inhibition of human immunodeficiency virus type 1 (HIV-1) replication by inducible expression of HIV-1 PR multimers. 
  • Principles and applications of a Tat-based assay for analyzing specific RNA-protein interactions in mammalian cells. 
  • RNA-sequence-mediated gene regulation in HIV-1. 
  • Recruitment of a protein complex containing Tat and cyclin T1 to TAR governs the species specificity of HIV-1 Tat. 
  • Recruitment of cyclin T1/P-TEFb to an HIV type 1 long terminal repeat promoter proximal RNA target is both necessary and sufficient for full activation of transcription. 
  • Regulation of 2',5'-oligoadenylate synthetase gene expression by interferons and platelet-derived growth factor. 
  • Sequence requirements for Rev multimerization in vivo. 
  • Small ubiquitin-related modifier-1 modification mediates resolution of CREB-dependent responses to hypoxia. 
  • Sp1 transcription factor is required for in vitro basal and Tat-activated transcription from the human immunodeficiency virus type 1 long terminal repeat. 
  • Subcellular localization of the human immunodeficiency virus trans-acting art gene product. 
  • Sustained induction of NF-kappa B is required for efficient expression of latent human immunodeficiency virus type 1. 
  • TAR RNA decoys inhibit tat-activated HIV-1 transcription after preinitiation complex formation. 
  • TAT peptide-functionalized gold nanostars: enhanced intracellular delivery and efficient NIR photothermal therapy using ultralow irradiance. 
  • Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling. 
  • The HIV-1 Tat protein: an RNA sequence-specific processivity factor? 
  • The VP16 transcription activation domain is functional when targeted to a promoter-proximal RNA sequence. 
  • The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. 
  • Tracking mesenchymal stromal cells using an ultra-bright TAT-functionalized plasmonic-active nanoplatform. 
  • Transcriptional cofactor CA150 regulates RNA polymerase II elongation in a TATA-box-dependent manner. 
  • Transcriptional trans activation by human immunodeficiency virus type 1 Tat requires specific coactivators that are not basal factors. 
  • Utilization of a mammalian cell-based RNA binding assay to characterize the RNA binding properties of picornavirus 3C proteinases.